Resources - MECHANISMS
Retatrutide in the UK: is it available, is it legal, when will it be licensed, and which trials are running here
Where retatrutide actually stands in the UK in autumn 2026: it has no licence, the MHRA says anyone selling it is doing so illegally, Lilly plans to file in the United States in early 2027, and eight registered trials have had UK sites. What "available" would require, how long tirzepatide took to go from licence to NHS, what is known about pens, and the licensed options that exist today.
People search for "retatrutide UK" for one of four reasons: they want to know whether they can get it, whether it is legal, when it will arrive, or whether they can join a trial. The answers, as of September 2026, are short. It is not available, because it is not licensed anywhere in the world. It is an unlicensed medicine, and the UK regulator has said in plain terms that selling it is illegal. It has no UK launch date, and the company that makes it has not yet filed for approval even in the United States. And yes, there have been trials with UK sites, though most have finished recruiting. This article sets out each answer with its source, explains what would have to happen before retatrutide could be prescribed here, uses tirzepatide's path as a guide to how long that takes, and ends with the licensed options that exist now. It is an account of regulatory status, not advice, and it does not tell anyone how to obtain anything.
What retatrutide is, in one paragraph
Retatrutide is an investigational once-weekly medicine developed by Eli Lilly. It activates three hormone receptors, GIP, GLP-1 and glucagon, where tirzepatide activates two and semaglutide one. In a 48-week phase 2 trial published in 2023, the highest dose produced an average weight loss of 24.2%, and the phase 3 programme, called TRIUMPH, began reporting in December 2025. Our retatrutide results article covers the trial figures and side effects in detail; this one is about where the compound stands in the UK.
Is retatrutide available in the UK?
No. A medicine can be prescribed and dispensed in the UK once it holds a marketing authorisation from the MHRA, the Medicines and Healthcare products Regulatory Agency. Retatrutide holds none, in the UK or in any other country. That means no NHS prescription, no private prescription, and no pharmacy stock, because there is no approved product for any of them to supply. In practice the single lawful route to receiving retatrutide is enrolment in a clinical trial, where the sponsor supplies the medicine under a trial authorisation and participants are monitored throughout.
This is worth stating flatly because the internet gives the opposite impression. Retatrutide is advertised on social media, sold by websites that look like pharmacies, and discussed on forums as if it were an established treatment. None of that changes its status. What is being sold is not a pharmaceutical product that has leaked from the supply chain; no commercial supply chain exists yet. It is material made by unknown manufacturers and labelled with the name.
Is retatrutide legal in the UK?
Two different legal questions get mixed together here. The first is whether retatrutide is a controlled drug under the Misuse of Drugs Act 1971. It is not, so possessing it for personal use is not in itself a criminal offence. Possessing it in order to supply it to someone else is a different matter, covered by the medicines rules below. The second is whether it can lawfully be sold or supplied. It cannot, subject to narrow exceptions such as authorised clinical trials: under regulation 46 of the Human Medicines Regulations 2012 a person may not sell or supply, or offer to sell or supply, a medicinal product that has no marketing authorisation, and retatrutide has none.
The MHRA addressed the point directly in a public statement on 24 July 2026, warning people against the online hype around retatrutide and saying that, because it has not been authorised for use in the UK, "anyone selling this product is doing so illegally". The same statement said that products sold under the name have not been tested for safety, quality or effectiveness, and that there is no guarantee they contain retatrutide at all. Of fake weight-loss medicines generally, it said some are contaminated with toxic substances. The enforcement risk falls on sellers, but the health risk falls on buyers, and that is the part the regulator was addressing.
When will retatrutide be licensed in the UK?
Nobody outside Lilly knows, and Lilly has not said. What is on the record is the American timetable. In its second-quarter 2026 results, published on 5 August 2026, the company said it plans to submit retatrutide to the US Food and Drug Administration in the first quarter of 2027 for obesity, obstructive sleep apnoea and knee osteoarthritis pain. It has not announced a date for an MHRA submission.
From there the timing is arithmetic and precedent. For a new molecule, the FDA has a standard review goal of ten months from the date it accepts an application, about twelve months from submission, which would put a US decision in early 2028; a priority review would be about four months shorter, and Lilly has not said which it expects. The MHRA can rely on a decision by a reference regulator such as the FDA under its international recognition procedure, which runs to a 60 or 110 day timetable but cannot begin before the reference approval exists. If Lilly takes that route, a UK licence before 2028 is unlikely. If it applies to the MHRA directly, as it did for the tirzepatide weight-management licence, the UK decision does not depend on the FDA and its timing cannot be predicted from the US plan. These are estimates built on a stated filing plan; filing dates slip, reviews get extended, and the honest answer to "when" is a range, not a date.
What tirzepatide's path tells us about NHS access
A licence is not the same as availability on the NHS. Tirzepatide shows the gap. The MHRA authorised Mounjaro for weight management in November 2023. NICE published its final recommendation, technology appraisal TA1026, in December 2024, thirteen months later. NHS England was then given an unusually long period to phase in access, starting in 2025 with the people at highest clinical need and extending over years rather than months. Someone who met the wider criteria could wait a long time after the licence for an NHS prescription. Private prescribing does not depend on NICE and began earlier.
| Step | What it means | Tirzepatide for weight management |
|---|
| Regulatory filing | Company submits trial data | US rolling submission 2022 to 2023; UK filing date not published |
| Marketing authorisation | MHRA licence; the medicine can then be prescribed | November 2023 |
| NICE appraisal | Decides whether the NHS should fund it | December 2024 (TA1026) |
| NHS rollout | Phased access by clinical priority | From 2025, over several years |
If retatrutide follows the same sequence, and nothing requires that it will, NHS access would come some time after a UK licence, and would begin with a narrow group. The tirzepatide rollout was phased because the eligible population was very large and NICE accepted that the NHS could not fund and deliver it to everyone at once, allowing up to 12 years. A medicine aimed at the same population would face the same constraint.
Retatrutide trials with UK sites
ClinicalTrials.gov, the US-run registry where most international trials are listed, showed eight retatrutide studies with sites in the United Kingdom when checked on 30 September 2026, out of 33 retatrutide studies worldwide. The table lists them with their registered status. Status changes, so the registry itself is the place to check.
| Registry number | What it studies | Phase | Status, 30 Sep 2026 |
|---|
| NCT05929066 | Obesity or overweight (TRIUMPH-1) | 3 | Completed |
| NCT05931367 | Obesity with knee osteoarthritis (TRIUMPH-4) | 3 | Completed |
| NCT06383390 | Cardiovascular and kidney outcomes, about 10,000 people | 3 | Active, not recruiting |
| NCT06859268 | Maintaining weight reduction in obesity | 3 | Active, not recruiting |
| NCT07232719 | Obesity or overweight | 3 | Active, not recruiting |
| NCT06297603 | Type 2 diabetes with kidney impairment | 3 | Active, not recruiting |
| NCT05936151 | Kidney function in overweight or obesity with chronic kidney disease | 2 | Completed |
| NCT07165028 | Fatty liver disease (master protocol of two medicines) | 3 | Recruiting |
Two things follow. First, the large obesity trials have finished enrolling, so the realistic chance of joining a retatrutide weight-loss trial in the UK now is small. Second, the trial that was still recruiting is a liver-disease study testing two medicines, with its own entry criteria, and a participant may be allocated to placebo or to a different medicine. Trials are not a back door to a drug: people are screened against strict criteria, randomised, and may never receive the active medicine. Anyone interested in research participation generally can search the NHS "Be Part of Research" service or ask a GP; the trial site, not a website, decides eligibility.
Retatrutide pens and what is sold online
"Retatrutide UK pen" is one of the most common searches on the subject. There is no approved retatrutide pen. If the medicine is licensed it will very probably come in a pre-filled device, as tirzepatide and semaglutide do, but that product does not yet exist outside trials. What is sold online as a retatrutide pen or vial is an unlicensed product. No regulator has checked what is in it, at what strength, or whether it is sterile, and the MHRA has reported falsified weight-loss pens in the UK that were confirmed to contain insulin instead of the labelled medicine, and warns that products from unregulated sellers may be contaminated. The trial results cannot be read across to these products, because the results describe a known compound at a known dose, and neither of those is known for something bought from a website.
The MHRA's advice in its July 2026 statement was practical: do not buy from unregulated websites or social media sellers, check that a pharmacy is registered with the General Pharmaceutical Council, and walk away from any offer of a GLP-1 medicine without a prescription. Separately, a suspected fake or a side effect from one can be reported to the MHRA through its Yellow Card scheme.
What is available now
- Semaglutide (Wegovy) for weight management: licensed; NHS access through specialist weight-management services for people who meet NICE criteria, recommended for a maximum of two years; also available from regulated private prescribers.
- Tirzepatide (Mounjaro) for weight management: licensed; NHS access being phased in by clinical priority under NICE TA1026; also available from regulated private prescribers.
- Both for type 2 diabetes: licensed and prescribed through NHS diabetes care where clinically appropriate.
- NHS weight-management programmes without medicines: available through a GP, and part of what NICE expects to accompany any prescription.
Our articles on Mounjaro side effects and on Ozempic and Wegovy side effects describe what the licences and trials say about those two medicines, and the comparison of retatrutide with tirzepatide sets the investigational drug beside the licensed one. A GP or pharmacist is the right person to say which option, if any, fits an individual.
How to check the status yourself
- Licence: search the MHRA products website for the medicine's name. If there is no entry, it is not licensed.
- NHS funding: search NICE guidance for a technology appraisal of the medicine.
- Trials: search ClinicalTrials.gov or the NHS Be Part of Research service, filtered to the United Kingdom.
- Pharmacy: check the General Pharmaceutical Council register before using any online pharmacy.
- Company timetable: regulatory filing plans are disclosed in the manufacturer's quarterly results.
This article describes the regulatory status of an investigational medicine as of 30 September 2026 and will date. Retatrutide is not licensed in the UK or anywhere else, and nothing here is medical advice or a suggestion that anyone should obtain or use it. Timelines are estimates based on the manufacturer's stated plans. Anyone seeking help with weight or type 2 diabetes should speak to a GP, an NHS weight-management service or a regulated prescriber about the licensed options. Vivera Education sells nothing.
Frequently asked
- Is retatrutide available in the UK?
- No. As of September 2026 retatrutide has no marketing authorisation in the UK or anywhere else. There is no licensed product for the NHS or a private prescriber to prescribe, and in practice the only lawful way to receive it is as a participant in a clinical trial.
- Is retatrutide legal in the UK?
- It is not a controlled drug, so possessing it for personal use is not in itself a criminal offence, but it is an unlicensed medicine, and possessing it in order to supply someone else is an offence. The MHRA stated in July 2026 that it has not been authorised for use in the UK and that anyone selling it is doing so illegally.
- When will retatrutide be available in the UK?
- No date has been announced. Lilly said in August 2026 that it plans to file with the US FDA in the first quarter of 2027 and has not announced an MHRA submission. A UK licence before 2028 looks unlikely on the US timetable, though that is an estimate, and NHS access would need a NICE appraisal after that.
- Are there retatrutide trials in the UK?
- Yes. ClinicalTrials.gov lists eight retatrutide studies with UK sites, including the completed TRIUMPH-1 obesity trial and a cardiovascular and kidney outcomes trial planned for about 10,000 people. As of September 2026 most are no longer recruiting; one liver-disease trial was still enrolling.
- Can I get retatrutide on the NHS?
- No. Retatrutide has no licence and no NICE recommendation, so outside a clinical trial it is not available on the NHS. The licensed weight-management medicines NICE recommends include semaglutide (Wegovy) and tirzepatide (Mounjaro), each with eligibility criteria.
- Can a private clinic or online pharmacy prescribe retatrutide?
- No. There is no licensed retatrutide product for a pharmacy to dispense. A website offering retatrutide with or without a prescription is not supplying a licensed, quality-assured medicine, whatever the label says.
- What is a retatrutide pen?
- In the trials, retatrutide was supplied by the sponsor as a once-weekly injection under the skin. No retatrutide pen has been approved for sale. Pens sold online as retatrutide are unlicensed products of unknown content, and the MHRA has warned that there is no guarantee they contain retatrutide at all.
- What can I use instead of retatrutide?
- The licensed medicines in the same family include semaglutide and tirzepatide, available through NHS weight-management or diabetes services for people who meet the criteria, or through a regulated private prescriber. A GP or pharmacist can explain which, if any, is appropriate.
The studies and sources behind this page
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.